| Title |
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo‐controlled study
|
|---|---|
| Published in |
Journal of Inherited Metabolic Disease, May 2014
|
| DOI | 10.1007/s10545-014-9715-6 |
| Pubmed ID | |
| Authors |
Christian J. Hendriksz, Barbara Burton, Thomas R. Fleming, Paul Harmatz, Derralynn Hughes, Simon A. Jones, Shuan‐Pei Lin, Eugen Mengel, Maurizio Scarpa, Vassili Valayannopoulos, Roberto Giugliani, STRIVE Investigators, Peter Slasor, Debra Lounsbury, Wolfgang Dummer |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 181 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 179 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 21 | 12% |
| Student > Bachelor | 21 | 12% |
| Researcher | 16 | 9% |
| Other | 16 | 9% |
| Student > Ph. D. Student | 13 | 7% |
| Other | 40 | 22% |
| Unknown | 54 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 60 | 33% |
| Biochemistry, Genetics and Molecular Biology | 18 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 6% |
| Agricultural and Biological Sciences | 9 | 5% |
| Nursing and Health Professions | 8 | 4% |
| Other | 20 | 11% |
| Unknown | 55 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 March 2022.
All research outputs
#2,728,914
of 25,918,104 outputs
Outputs from Journal of Inherited Metabolic Disease
#105
of 2,033 outputs
Outputs of similar age
#26,586
of 244,869 outputs
Outputs of similar age from Journal of Inherited Metabolic Disease
#1
of 21 outputs
Altmetric has tracked 25,918,104 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,033 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 244,869 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.